Prognosis according to the timing of recurrence in breast cancer
- Authors
- Lee, Young Joo; Jung, Seung Pil; Bae, Jeoung Won; Yang, Sun Moon; You, Ji Young; Bae, Soo Youn
- Issue Date
- Jan-2023
- Publisher
- 대한외과학회
- Keywords
- Breast neoplasms; Prognosis; Recurrence; Time
- Citation
- Annals of Surgical Treatment and Research, v.104, no.1, pp 1 - 9
- Pages
- 9
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Annals of Surgical Treatment and Research
- Volume
- 104
- Number
- 1
- Start Page
- 1
- End Page
- 9
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/63019
- DOI
- 10.4174/astr.2023.104.1.1
- ISSN
- 2288-6575
2288-6796
- Abstract
- Purpose
Clinically, breast cancer can be divided into 4 subtypes based on the presence of hormone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67. Because the pattern and time of recurrence vary according to the subtype, we evaluated whether there was a difference in overall survival (OS) among the subtypes according to the time and type of recurrence.
Methods
A total of 2,730 patients who underwent breast cancer surgery were analyzed. Early and late recurrence were defined as recurrence within and after 5 years of diagnosis, respectively. Recurrence type was categorized as locoregional recurrence or systemic recurrence.
Results
Hormone receptor-positive tumors were significantly more frequent in the late recurrence group than in the early recurrence group (estrogen receptor positive, 47.8% [early] vs. 78.7% [late]). However, there was no difference in the rate of HER2 overexpression (HER2+, 38.1% [early] vs.39.0% [late]). In subgroup analysis, early recurrence was a significant prognostic factor for OS in all subtypes. However, late recurrence was a significant prognostic factor for OS only in the luminal B subtype (hazard ratio of 4.30). In addition, the luminal B type had the highest proportion in late recurrence patients (63.2%).
Conclusion
The luminal B subtype had a high rate of late recurrence, and late recurrence was a poor prognostic factor for OS only in this subgroup. Therefore, further targeted treatments for luminal B breast cancer are needed and patients with this subtype require close long-term surveillance.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Anesthesiology and Pain Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.